Drug

InnoCare's Mesutoclax Wins CDE Approval for Registrational Phase III Trial With Orelabrutinib in Relapsed/Refractory MZL – Fifth Registrational Study for China's First BTD‑Designated BCL2 Inhibitor
Clinical trial approval / initiationHKG: 9969

InnoCare’s Mesutoclax Wins CDE Approval for Registrational Phase III Trial With Orelabrutinib in Relapsed/Refractory MZL – Fifth Registrational Study for China’s First BTD‑Designated BCL2 Inhibitor

InnoCare Pharma (HKG: 9969; SHA: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced that the Center for Drug Evaluation (CDE) of China's National…

Laekna's LAE102 Delivers Promising Weight Loss With Lean Mass Gains in Completed 24‑Week Low‑Dose Monotherapy Cohorts – Selective ActRIIA Antibody Well Tolerated, High‑Dose Cohort Fully Enrolled

Laekna’s LAE102 Delivers Promising Weight Loss With Lean Mass Gains in Completed 24‑Week Low‑Dose Monotherapy Cohorts – Selective ActRIIA Antibody Well Tolerated, High‑Dose Cohort Fully Enrolled

CARsgen Doses First Patient in Registrational Phase I Trial of CT0596 – Allogeneic BCMA CAR‑T Built on THANK‑u Plus® Platform Advances Toward Relapsed/Refractory Multiple Myeloma

CARsgen Doses First Patient in Registrational Phase I Trial of CT0596 – Allogeneic BCMA CAR‑T Built on THANK‑u Plus® Platform Advances Toward Relapsed/Refractory Multiple Myeloma

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
CF PharmTechClinical trial approval / initiation

CF PharmTech Wins NMPA Approval for Olopatadine Mometasone Combo Trial – Fixed-Dose Nasal Spray Targets Moderate-to-Severe Allergic Rhinitis

CancerClinical trial approval / initiation

Dongcheng Pharma Doses First Patient in 225Ac-LNC1011 Phase I/II Trial – PSMA-Targeted Alpha Radiotherapy for Metastatic Prostate Cancer

ADC / XDCBio-Thera Solutions

Bio-Thera Wins NMPA Approval for BAT8008 BAT1006 Trastuzumab Combo Trial – Dual HER2 Trop2 Targeting in Advanced Solid Tumors

Novo Nordisk's IcoSema Wins NMPA Approval – Once-Weekly Insulin-Semaglutide Combo Targets China Type 2 Diabetes Market
DiabetesHot targets

Novo Nordisk’s IcoSema Wins NMPA Approval – Once-Weekly Insulin-Semaglutide Combo Targets China Type 2 Diabetes Market

Show More